



thor medical

Invitation to presentation of Thor Medical ASA's second half results 2023

21.2.2024 08:03:21 CET | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

Thor Medical ASA will release its second half results on Wednesday 28 February 2024 at 07:00 am (CEST).

A presentation of the results followed by a Q&A session will be held on the same day at 08:00 am at Carnegie's offices at Aker Brygge, Fjordalleen 16, and through a live webcast. The presentation and the Q&A session can be followed through a live webcast from our website www.thormedical.no or [Thor Medical Webcast Q4 2023 \(royalcast.com\)](http://Thor Medical Webcast Q4 2023 (royalcast.com)).

Disclosure regulation

This information is required to be disclosed under Section 5-12 of the Securities Trading Act.

Contacts

- Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no

About Thor Medical ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no.

Attachments

- [Download announcement as PDF.pdf](#)